XML 94 R39.htm IDEA: XBRL DOCUMENT v2.4.0.8
Collaborative Arrangements (Details) (USD $)
 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 3 Months Ended 6 Months Ended 22 Months Ended
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2013
Jun. 30, 2012
Dec. 31, 2012
Jun. 30, 2013
Janssen Pharmaceutica, N.V.
Jun. 30, 2012
Janssen Pharmaceutica, N.V.
Jun. 30, 2013
Janssen Pharmaceutica, N.V.
Jun. 30, 2012
Janssen Pharmaceutica, N.V.
Dec. 31, 2006
Janssen Pharmaceutica, N.V.
Jun. 30, 2013
Mitsubishi Tanabe Pharma Corporation
Jun. 30, 2012
Mitsubishi Tanabe Pharma Corporation
Jun. 30, 2012
Mitsubishi Tanabe Pharma Corporation
Dec. 31, 2011
Mitsubishi Tanabe Pharma Corporation
Dec. 31, 2009
Mitsubishi Tanabe Pharma Corporation
Apr. 30, 2011
Cystic Fibrosis Foundation Therapeutics Incorporated
Jun. 30, 2013
Cystic Fibrosis Foundation Therapeutics Incorporated
payment
Sep. 30, 2012
Cystic Fibrosis Foundation Therapeutics Incorporated
Jun. 30, 2012
Cystic Fibrosis Foundation Therapeutics Incorporated
Jun. 30, 2013
Cystic Fibrosis Foundation Therapeutics Incorporated
Jun. 30, 2012
Cystic Fibrosis Foundation Therapeutics Incorporated
Dec. 31, 2006
Cystic Fibrosis Foundation Therapeutics Incorporated
Jun. 30, 2013
Alios Bio Pharma Inc
lines
Jun. 30, 2012
Alios Bio Pharma Inc
Jun. 30, 2013
Alios Bio Pharma Inc
lines
Jun. 30, 2012
Alios Bio Pharma Inc
Mar. 31, 2013
Alios Bio Pharma Inc
Dec. 31, 2012
Alios Bio Pharma Inc
Jun. 13, 2011
Alios Bio Pharma Inc
Schedule of Collaborative Arrangements                                                          
Drug development costs to be paid by collaborator (as a percent)           50.00%       50.00%                                      
Up-front license payment                   $ 165,000,000                                      
Deferred revenue related to up-front license payment           37,300,000   37,300,000                                          
Total contingent milestone payments earned           350,000,000                                              
Notice period required to terminate without cause (in years)           1 year                                              
Notice period required for termination after first commercial sale ( in years)           10 years                                              
Collaborative revenues recognized                                                          
Royalty revenues 49,120,000 33,480,000 92,693,000 72,461,000   44,070,000 27,970,000 83,114,000 60,854,000                                        
Amortized portion of up-front payment           3,107,000 3,107,000 6,214,000 6,214,000                                        
Net reimbursement (payment) for telaprevir development costs           37,000 (927,000) 9,000 (2,066,000)                                        
Reimbursement for manufacturing services           0 0 10,299,000 4,449,000                                        
Collaborative revenues 6,841,000 11,552,000 24,255,000 35,933,000   3,144,000 2,180,000 16,522,000 8,597,000   0 4,800,000 18,900,000       4,244,000   4,527,000 7,803,000 8,457,000                
Total revenues 310,750,000 418,305,000 639,118,000 857,042,000   47,214,000 30,150,000 99,636,000 69,451,000                                        
License fee paid upon amendment of agreement                             105,000,000                            
Milestone payment received                           65,000,000     9,300,000 9,300,000       1,500,000              
Notice period required to terminate without cause (in days)                     60 days                                    
Collaborative funding                               75,000,000                          
Number of years over which funding will be made (in years)                               5 years                          
Number of commercial milestone payments for achievement of certain sales levels for corrector compound such as VX-809 or VX-661 (in payments)                                 2                        
Up-front payment                                                         60,000,000
Milestone payments                                                     60,000,000    
Development milestone payments, maximum                                                     312,500,000    
Commercial milestone payments, maximum                                             750,000,000            
Notice period for termination of contract due to technical failure (in days)                                             30 days            
Notice period for termination of contract after completion of clinical trials (in days)                                             60 days            
Latest expiration period for royalty obligation after first commercial sale in country unless contract is terminated earlier (in years)                                             10 years            
Noncontrolling Interest (Alios)                                                          
Number of lines on balance sheet where noncontrolling interest is reported                                             2   2        
Loss (income) before provision for (benefit from) income taxes                                             6,824,000 4,467,000 12,121,000 9,491,000      
Decrease (increase) in fair value of contingent milestone and royalty payments                                             80,000 (56,170,000) 2,820,000 (55,200,000)      
Provision for (benefit from) income taxes (1,799,000) 20,063,000 (132,112,000) 20,095,000                                     (2,357,000) 21,240,000 (5,783,000) 18,960,000      
Net loss (income) attributable to noncontrolling interest (Alios) (4,547,000) 30,463,000 (9,158,000) 26,749,000                                     4,547,000 (30,463,000) 9,158,000 (26,749,000)      
Restricted cash and cash equivalents (Alios) 58,288,000 [1]   58,288,000 [1]   69,983,000 [1]                                   58,288,000   58,288,000     69,983,000  
Prepaid expenses and other current assets 43,231,000 [1]   43,231,000 [1]   24,673,000 [1]                                   4,115,000   4,115,000     672,000  
Property and equipment, net 581,738,000 [1]   581,738,000 [1]   433,609,000 [1]                                   1,478,000   1,478,000     1,728,000  
Intangible assets                                             250,600,000   250,600,000     250,600,000  
Goodwill 30,992,000 [1]   30,992,000 [1]   30,992,000 [1]                                   4,890,000   4,890,000     4,890,000  
Other assets 4,287,000 [1]   4,287,000 [1]   9,668,000 [1]                                   861,000   861,000     861,000  
Accounts payable 48,570,000 [1]   48,570,000 [1]   101,292,000 [1]                                   1,666,000   1,666,000     1,054,000  
Accrued expenses 260,849,000 [1]   260,849,000 [1]   264,884,000 [1]                                   5,294,000   5,294,000     6,099,000  
Deferred tax liability 149,706,000 [1]   149,706,000 [1]   280,367,000 [1]                                   149,706,000   149,706,000     152,781,000  
Other liabilities, excluding current portion 16,049,000 [1]   16,049,000 [1]   13,902,000 [1]                                   1,078,000   1,078,000     1,625,000  
Redeemable noncontrolling interest (Alios) 39,214,000 [1]   39,214,000 [1]   38,530,000 [1]                                   39,214,000   39,214,000     38,530,000  
Noncontrolling interest (Alios) $ 186,996,000 [1]   $ 186,996,000 [1]   $ 196,672,000 [1]                                   $ 186,996,000   $ 186,996,000     $ 196,672,000  
[1] Amounts include the assets and liabilities of Vertex’s variable interest entity (“VIE”), Alios BioPharma, Inc. (“Alios”). Vertex’s interests and obligations with respect to the VIE’s assets and liabilities are limited to those accorded to Vertex in its agreement with Alios. See Note C, "Collaborative Arrangements," to these condensed consolidated financial statements for amounts.